Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

1.

Modelling Signalling Networks from Perturbation Data.

Dorel M, Klinger B, Gross T, Sieber A, Prahallad A, Bosdriesz E, Wessels L, Blüthgen N.

Bioinformatics. 2018 Jun 19. doi: 10.1093/bioinformatics/bty473. [Epub ahead of print]

PMID:
29931053
2.

Perturbation-response genes reveal signaling footprints in cancer gene expression.

Schubert M, Klinger B, Klünemann M, Sieber A, Uhlitz F, Sauer S, Garnett MJ, Blüthgen N, Saez-Rodriguez J.

Nat Commun. 2018 Jan 2;9(1):20. doi: 10.1038/s41467-017-02391-6.

3.

An immediate-late gene expression module decodes ERK signal duration.

Uhlitz F, Sieber A, Wyler E, Fritsche-Guenther R, Meisig J, Landthaler M, Klinger B, Blüthgen N.

Mol Syst Biol. 2017 Sep 25;13(9):944. doi: 10.15252/msb.20177986. No abstract available.

4.

An immediate-late gene expression module decodes ERK signal duration.

Uhlitz F, Sieber A, Wyler E, Fritsche-Guenther R, Meisig J, Landthaler M, Klinger B, Blüthgen N.

Mol Syst Biol. 2017 May 3;13(5):928. doi: 10.15252/msb.20177554. Erratum in: Mol Syst Biol. 2017 Sep 25;13(9):944.

5.

Drug Resistance Mechanisms in Colorectal Cancer Dissected with Cell Type-Specific Dynamic Logic Models.

Eduati F, Doldàn-Martelli V, Klinger B, Cokelaer T, Sieber A, Kogera F, Dorel M, Garnett MJ, Blüthgen N, Saez-Rodriguez J.

Cancer Res. 2017 Jun 15;77(12):3364-3375. doi: 10.1158/0008-5472.CAN-17-0078. Epub 2017 Apr 5.

6.

The role of the cancer stem cell marker CD271 in DNA damage response and drug resistance of melanoma cells.

Redmer T, Walz I, Klinger B, Khouja S, Welte Y, Schäfer R, Regenbrecht C.

Oncogenesis. 2017 Jan 23;6(1):e291. doi: 10.1038/oncsis.2016.88.

7.

Annexin A1 sustains tumor metabolism and cellular proliferation upon stable loss of HIF1A.

Rohwer N, Bindel F, Grimm C, Lin SJ, Wappler J, Klinger B, Blüthgen N, Du Bois I, Schmeck B, Lehrach H, de Graauw M, Goncalves E, Saez-Rodriguez J, Tan P, Grabsch HI, Prigione A, Kempa S, Cramer T.

Oncotarget. 2016 Feb 9;7(6):6693-710. doi: 10.18632/oncotarget.6793.

8.

Hypoxia-induced gene expression results from selective mRNA partitioning to the endoplasmic reticulum.

Staudacher JJ, Naarmann-de Vries IS, Ujvari SJ, Klinger B, Kasim M, Benko E, Ostareck-Lederer A, Ostareck DH, Bondke Persson A, Lorenzen S, Meier JC, Blüthgen N, Persson PB, Henrion-Caude A, Mrowka R, Fähling M.

Nucleic Acids Res. 2015 Mar 31;43(6):3219-36. doi: 10.1093/nar/gkv167. Epub 2015 Mar 8.

9.

Computer-assisted curation of a human regulatory core network from the biological literature.

Thomas P, Durek P, Solt I, Klinger B, Witzel F, Schulthess P, Mayer Y, Tikk D, Blüthgen N, Leser U.

Bioinformatics. 2015 Apr 15;31(8):1258-66. doi: 10.1093/bioinformatics/btu795. Epub 2014 Nov 29.

PMID:
25433699
10.

Consequences of feedback in signal transduction for targeted therapies.

Klinger B, Blüthgen N.

Biochem Soc Trans. 2014 Aug;42(4):770-5. doi: 10.1042/BST20140130. Review.

PMID:
25109956
11.

Network quantification of EGFR signaling unveils potential for targeted combination therapy.

Klinger B, Sieber A, Fritsche-Guenther R, Witzel F, Berry L, Schumacher D, Yan Y, Durek P, Merchant M, Schäfer R, Sers C, Blüthgen N.

Mol Syst Biol. 2013;9:673. doi: 10.1038/msb.2013.29.

12.

Multilevel regulation of HIF-1 signaling by TTP.

Fähling M, Persson AB, Klinger B, Benko E, Steege A, Kasim M, Patzak A, Persson PB, Wolf G, Blüthgen N, Mrowka R.

Mol Biol Cell. 2012 Oct;23(20):4129-41. doi: 10.1091/mbc.E11-11-0949. Epub 2012 Aug 23.

13.

Reverse engineering a hierarchical regulatory network downstream of oncogenic KRAS.

Stelniec-Klotz I, Legewie S, Tchernitsa O, Witzel F, Klinger B, Sers C, Herzel H, Blüthgen N, Schäfer R.

Mol Syst Biol. 2012;8:601. doi: 10.1038/msb.2012.32.

14.

Discovering causal signaling pathways through gene-expression patterns.

Parikh JR, Klinger B, Xia Y, Marto JA, Blüthgen N.

Nucleic Acids Res. 2010 Jul;38(Web Server issue):W109-17. doi: 10.1093/nar/gkq424. Epub 2010 May 21.

15.

A multilocular radiolucency. Botryoid odontogenic cyst.

Chi AC, Neville BW, Klinger BJ.

J Am Dent Assoc. 2007 Aug;138(8):1102-3. No abstract available.

PMID:
17670878
16.

The product space conditions the development of nations.

Hidalgo CA, Klinger B, Barabási AL, Hausmann R.

Science. 2007 Jul 27;317(5837):482-7.

17.

The mating pair stabilization protein, TraN, of the F plasmid is an outer-membrane protein with two regions that are important for its function in conjugation.

Klimke WA, Rypien CD, Klinger B, Kennedy RA, Rodriguez-Maillard JM, Frost LS.

Microbiology. 2005 Nov;151(Pt 11):3527-40.

PMID:
16272376
18.
19.
20.

The disruptive behavior disorders in the psychiatric emergency service.

Breslow RE, Klinger BI, Erickson BJ.

Gen Hosp Psychiatry. 1999 May-Jun;21(3):214-9.

PMID:
10378115
21.

Patients with Laron syndrome have Osteopenia/Osteoporosis.

Laron Z, Klinger B, Silbergeld A.

J Bone Miner Res. 1999 Jan;14(1):156-7. No abstract available.

22.

Development of hyperandrogenism during treatment with insulin-like growth factor-I (IGF-I) in female patients with Laron syndrome.

Klinger B, Anin S, Silbergeld A, Eshet R, Laron Z.

Clin Endocrinol (Oxf). 1998 Jan;48(1):81-7.

PMID:
9509072
24.

County drift: a type of geographic mobility of chronic psychiatric patients.

Breslow RE, Klinger BI, Erickson BJ.

Gen Hosp Psychiatry. 1998 Jan;20(1):44-7.

PMID:
9506253
26.

[Nursing anamnesis--determining the emphasis].

Klinger B.

Kinderkrankenschwester. 1997 Aug;16(8):320-2. German. No abstract available.

PMID:
9370599
27.

Intronic mutation in the growth hormone (GH) receptor gene from a girl with Laron syndrome and extremely high serum GH binding protein: extended phenotypic study in a very large pedigree.

Silbergeld A, Dastot F, Klinger B, Kanety H, Eshet R, Amselem S, Laron Z.

J Pediatr Endocrinol Metab. 1997 May-Jun;10(3):265-74.

PMID:
9388817
28.

Growth hormone increases and insulin-like growth factor-I decreases circulating lipoprotein(a)

Laron Z, Wang XL, Klinger B, Silbergeld A, Wilcken DE.

Eur J Endocrinol. 1997 Apr;136(4):377-81.

PMID:
9150696
29.

Growth during and 2 years after stopping GH treatment in prepubertal children with idiopathic short stature.

Laron Z, Klinger B, Anin S, Pertzelan A, Lilos P.

J Pediatr Endocrinol Metab. 1997 Mar-Apr;10(2):191-6.

PMID:
9364352
30.

Time study of psychiatric emergency service evaluations.

Breslow RE, Klinger BI, Erickson BJ.

Gen Hosp Psychiatry. 1997 Jan;19(1):1-4.

PMID:
9034804
32.

Specific detection of his-tagged proteins with recombinant anti-His tag scFv-phosphatase or scFv-phage fusions.

Lindner P, Bauer K, Krebber A, Nieba L, Kremmer E, Krebber C, Honegger A, Klinger B, Mocikat R, Plückthun A.

Biotechniques. 1997 Jan;22(1):140-9.

PMID:
8994661
33.

Characteristics of managed care patients in a psychiatric emergency service.

Breslow RE, Klinger BI, Erickson BJ.

Psychiatr Serv. 1996 Nov;47(11):1259-61.

PMID:
8916248
34.

Insulin-like growth factor-I raises serum procollagen levels in children and adults with Laron syndrome.

Klinger B, Jensen LT, Silbergeld A, Laron Z.

Clin Endocrinol (Oxf). 1996 Oct;45(4):423-9.

PMID:
8959080
35.

Insulin-like growth factor-I decreases serum lipoprotein (a) during long-term treatment of patients with Laron syndrome.

Laron Z, Wang XL, Klinger B, Silbergeld A, Wilcken DE.

Metabolism. 1996 Oct;45(10):1263-6.

PMID:
8843182
36.

Growth hormone treatment increases circulating lipoprotein(a) in children with chronic renal failure.

Laron Z, Wang XL, Klinger B, Silbergeld A, Davidovits M, Eisenstein B, Wilcken DE.

J Pediatr Endocrinol Metab. 1996 Sep-Oct;9(5):533-7.

PMID:
8961129
37.
38.

Acute intoxication and substance abuse among patients presenting to a psychiatric emergency service.

Breslow RE, Klinger BI, Erickson BJ.

Gen Hosp Psychiatry. 1996 May;18(3):183-91.

PMID:
8739011
39.

Intranasal administration of the GHRP hexarelin accelerates growth in short children.

Laron Z, Frenkel J, Deghenghi R, Anin S, Klinger B, Silbergeld A.

Clin Endocrinol (Oxf). 1995 Nov;43(5):631-5.

PMID:
8548949
40.
41.

Three year IGF-I treatment of children with Laron syndrome.

Klinger B, Laron Z.

J Pediatr Endocrinol Metab. 1995 Jul-Sep;8(3):149-58.

PMID:
8521188
42.

Crisis hospitalization in a psychiatric emergency service.

Breslow RE, Klinger BI, Erickson BJ.

New Dir Ment Health Serv. 1995 Fall;(67):5-12.

PMID:
7476810
43.

Renal function in Laron syndrome patients treated by insulin-like growth factor-I.

Klinger B, Laron Z.

Pediatr Nephrol. 1994 Dec;8(6):684-8.

PMID:
7696105
44.

IGF-I treatment of adult patients with Laron syndrome: preliminary results.

Laron Z, Klinger B.

Clin Endocrinol (Oxf). 1994 Nov;41(5):631-8.

PMID:
7530175
45.

Growth hormone releasing activity by intranasal administration of a synthetic hexapeptide (hexarelin).

Laron Z, Frenkel J, Gil-Ad I, Klinger B, Lubin E, Wuthrich P, Boutignon F, Lengerts V, Deghenghi R.

Clin Endocrinol (Oxf). 1994 Oct;41(4):539-41.

PMID:
7955465
46.

Comparative effects of GH, IGF-I and insulin on serum sex hormone binding globulin.

Gafny M, Silbergeld A, Klinger B, Wasserman M, Laron Z.

Clin Endocrinol (Oxf). 1994 Aug;41(2):169-75.

PMID:
7923821
47.

Serum growth hormone-binding protein (GHBP) activity is decreased by administration of insulin-like growth factor I in three Laron syndrome siblings with normal GHBP.

Silbergeld A, Klinger B, Keret R, Eshet R, Almonté AS, Laron Z.

Proc Soc Exp Biol Med. 1994 Jul;206(3):324-7.

PMID:
8016174
48.

Laron syndrome: clinical features, molecular pathology and treatment.

Laron Z, Klinger B.

Horm Res. 1994;42(4-5):198-202.

PMID:
7868073
49.

Laron syndrome due to a post-receptor defect: response to IGF-I treatment.

Laron Z, Klinger B, Eshet R, Kaneti H, Karasik A, Silbergeld A.

Isr J Med Sci. 1993 Dec;29(12):757-63.

PMID:
8300382
50.

Modulation of IGF-I receptors by exogenous hGH treatment in constitutionally short children.

Eshet R, Klinger B, Silbergeld A, Laron Z.

Clin Endocrinol (Oxf). 1993 Dec;39(6):687-93.

PMID:
8287588

Supplemental Content

Loading ...
Support Center